Annals of surgical oncology · 2025
Immediate Lymphatic Reconstruction (ILR) for the Prevention of Lymphedema: A Meta-analysis of Prospective Clinical Trials.
СтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brown Stav, Shen Yizhuo, Klimitz Felix J, Nair Meera, Mattia Alexzandra, Kauke-Navarro Martin, Noel Olivier F, Wo Luccie, Pomahac Bohdan, Lofti Parisa, Golshan Mehra, Haykal Siba
Аннотация
BACKGROUND: Despite the growing use of immediate lymphatic reconstruction (ILR) for preventing lymphedema, prospective long-term data on its efficacy remain limited.
OBJECTIVE: This study aimed to analyze long-term, prospective outcomes of ILR, utilizing all available outcome measures.
METHODS: Outcome data included the pooled cumulative incidence of lymphedema (assessed by limb measurements), odds ratio (OR), and relative risk (RR) for lymphedema development in patients who underwent ILR versus those who did not. Only prospective clinical trials with a minimum of 12 months of follow-up were included.
RESULTS: Nine prospective studies (2011-2024) were included, totaling 791 patients, with 460 undergoing ILR and an average follow-up of 20.6 ± 4.8 months. On average, 1.9 ± 0.4 anastomoses were performed per patient. ILR was associated with a significantly lower incidence of lymphedema: 9% (95% confidence interval [CI] 1-16%) compared with 29% (95% CI 11-46%) in the non-ILR group. Patients who received ILR had 69% lower odds of developing lymphedema compared with those without ILR (OR 0.31, 95% CI 0.19-0.51). A 58% reduction in lymphedema risk was also observed among ILR recipients (RR 0.42, 95% CI 0.26-0.68).
CONCLUSION: This meta-analysis summarizing prospective data with a minimum of 12-month follow-up represents the largest evaluation to date of ILR with extended follow-up for lymphedema prevention. The findings demonstrate that ILR significantly reduces the incidence, odds, and risk of lymphedema, supporting its role as an effective preventive strategy in at-risk patients.
OBJECTIVE: This study aimed to analyze long-term, prospective outcomes of ILR, utilizing all available outcome measures.
METHODS: Outcome data included the pooled cumulative incidence of lymphedema (assessed by limb measurements), odds ratio (OR), and relative risk (RR) for lymphedema development in patients who underwent ILR versus those who did not. Only prospective clinical trials with a minimum of 12 months of follow-up were included.
RESULTS: Nine prospective studies (2011-2024) were included, totaling 791 patients, with 460 undergoing ILR and an average follow-up of 20.6 ± 4.8 months. On average, 1.9 ± 0.4 anastomoses were performed per patient. ILR was associated with a significantly lower incidence of lymphedema: 9% (95% confidence interval [CI] 1-16%) compared with 29% (95% CI 11-46%) in the non-ILR group. Patients who received ILR had 69% lower odds of developing lymphedema compared with those without ILR (OR 0.31, 95% CI 0.19-0.51). A 58% reduction in lymphedema risk was also observed among ILR recipients (RR 0.42, 95% CI 0.26-0.68).
CONCLUSION: This meta-analysis summarizing prospective data with a minimum of 12-month follow-up represents the largest evaluation to date of ILR with extended follow-up for lymphedema prevention. The findings demonstrate that ILR significantly reduces the incidence, odds, and risk of lymphedema, supporting its role as an effective preventive strategy in at-risk patients.